Abstract
The global COVID-19 pandemic caused by SARS CoV-2 is causing both mortality/morbidity and collateral social and economic damage related to public panic and aggressive public policy measures to contain the disease worldwide.(1) The epidemic appears to have taken hold much more slowly in sub-Saharan Africa than most of the world.(2) Antibody testing to evaluate the population proportion previously infected with SARS CoV-2 has the potential to guide public policy, but has not been reported so far for sub-Saharan Africa.
Competing Interest Statement
John H. Kempen serves as a consultant (DSMC Chair) for Gilead Sciences.
Funding Statement
Funding: Laboratory testing in the study was supported by International Clinical Laboratories, Addis Ababa, Ethiopia. Compliance expenses were paid by Massachusetts Eye and Ear, Boston, MA, USA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. MyungSung Medical College IRB 2. Partners Healthcare IRB 3. Addis Ababa Regional Health Bureau
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: Laboratory testing in the study was supported by International Clinical Laboratories, Addis Ababa, Ethiopia. Compliance expenses were paid by Massachusetts Eye and Ear, Boston, MA, USA.
Financial Disclosures: John H. Kempen, MD, PhD is a consultant (Data and Safety Monitoring Committee Chair) for Gilead Sciences, Inc.
Data Availability
Not available
